# Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

> **NCT07738887** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 44 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ibrutinib Oral Tablet
- **DRUG:** Venetoclax Oral Tablet
- **DRUG:** Epcoritamab

## Key facts

- **NCT ID:** NCT07738887
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-31
- **Primary completion:** 2029-12-31
- **Final completion:** 2032-06-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-07-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738887, "Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07738887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*